Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $119000.0.

  • Pharma's Depreciation & Amortization (CF) fell 1793.1% to $119000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $571000.0, marking a year-over-year decrease of 950.87%. This contributed to the annual value of $618000.0 for FY2025, which is 298.27% down from last year.
  • Pharma's Depreciation & Amortization (CF) amounted to $119000.0 in Q3 2025, which was down 1793.1% from $141000.0 recorded in Q2 2025.
  • In the past 5 years, Pharma's Depreciation & Amortization (CF) registered a high of $172000.0 during Q4 2022, and its lowest value of $119000.0 during Q3 2025.
  • Its 5-year average for Depreciation & Amortization (CF) is $157315.8, with a median of $160000.0 in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 12133.33% in 2021, then crashed by 1793.1% in 2025.
  • Over the past 5 years, Pharma's Depreciation & Amortization (CF) (Quarter) stood at $166000.0 in 2021, then rose by 3.61% to $172000.0 in 2022, then dropped by 6.98% to $160000.0 in 2023, then fell by 1.88% to $157000.0 in 2024, then fell by 24.2% to $119000.0 in 2025.
  • Its last three reported values are $119000.0 in Q3 2025, $141000.0 for Q2 2025, and $154000.0 during Q1 2025.